Chemomab Therapeutics Ltd. (CMMB) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$2.73

From 52W high−25.43%

Volume175705.00

Market cap$19.13M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$2.73

From 52W high

−25.43%

Volume

175705.00

Market cap

$19.13M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.6x

P/E (TTM)

—

RSI (14)

62.8

MomentumView details →

1D Return

−6.79%

YTD Return

+64.24%

SummaryUpdated Jun 1, 2026

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) is a clinical-stage biotechnology company founded in 2011 and headquartered in Tel Aviv, Israel. The company went public in February 2019 and was formerly known as Anchiano Therapeutics Ltd. before changing its name to Chemomab Therapeutics in March 2021. Chemomab focuses on developing innovative therapeutics for the treatment of inflammation and fibrosis, conditions that affect millions of patients worldwide and represent significant unmet medical needs.

Ask drillr about Chemomab Therapeutics Ltd. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.6x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.2x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−87.53%

ROA (TTM)

−74.25%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+56.96%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+97.94%

EBITDA YoY

+37.26%

MomentumView details →

1D Return

−6.79%

YTD Return

+64.24%

1Y Return

+2.26%

RSI (14)

62.8

vs 50D SMA

+32.29%

vs 200D SMA

+46.90%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

6.41x

Quick Ratio

6.41x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.27

EPS Surprise

−80.00%

Beats (12Q)

5/12

Next Q EPS Est

−$0.01

Avg Surprise (4Q)

−212.50%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−7.60M

Op. CF (TTM)

−11.22M

Next earningsNov 6, 2026 →

Latest newsMore news →

Chemomab Therapeutics announced that its planned merger with Scipher Medicine is advancing, with closing expected by year-end.32d ago

Chemomab Therapeutics announced its second quarter 2026 financial results and provided a corporate update.32d ago

Similar companies

VYNE Therapeutics Inc.VYNE Allarity Therapeutics, Inc.ALLR Marker Therapeutics, Inc.MRKR Sensei Biotherapeutics, Inc.SNSE Lantern Pharma Inc.LTRN Lisata Therapeutics, Inc.LSTA Find similar companies →

Latest newsMore news →

Chemomab Therapeutics announced that its planned merger with Scipher Medicine is advancing, with closing expected by year-end.32d ago Chemomab Therapeutics announced its second quarter 2026 financial results and provided a corporate update.32d ago